Xilio Therapeutics

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. Xilio went public in November 2021 (NASDAQ: XLO).

Headquarters Waltham, MA
Website xiliotx.com​
Pipeline Preclinical
Twitter @xiliotx​
LinkedIn Xilio Therapeutics​